G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adults With T1D: a Phase 3 B Multi-Centered, Randomized, Controlled, Single Blind, 2-Way Crossover Study to Evaluate Efficacy and Safety

Trial Profile

G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adults With T1D: a Phase 3 B Multi-Centered, Randomized, Controlled, Single Blind, 2-Way Crossover Study to Evaluate Efficacy and Safety

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors XERIS Pharmaceuticals
  • Most Recent Events

    • 26 Jun 2018 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Jun 2018 Results presented in a Xeris Pharmaceuticals media release.
    • 19 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top